Thyrocare Technologies Ltd
Thyrocare Technologies Q2 FY26 earnings call: Revenue & Margins
Q2 FY26 earnings call: what management said on revenue, margins and capex.
The short version
Thyrocare is currently achieving mid-teen volume growth quaterly and expects this to continue. Thyrocare expects stable margins with some seasonal dip in Q3 followed by recovery in Q4 FY '26.
From Thyrocare Technologies Ltd's Q2 FY26 earnings-call transcript · updated 16 Oct 2026.
Revenue & Sales Performance
- Thyrocare is currently achieving mid-teen volume growth quaterly and expects this to continue.
- With the emergence of GLP-1 weight loss drugs, there is an anticipated significant opportunity that could drive higher volume growth in coming years, potentially high-teens by FY '27/'28, though it's early to firm up guidance.
- The company expects consistent revenue growth, with mid-teens growth outlook for the second half of FY '26, supported by a strong base.
- Franchisee network expansion is robust, adding 100-150 net franchisees monthly over the last 12-18 months.
- Partnership (primarily online) business is growing faster than franchise (offline), with 35% revenue growth in partnerships vs 20% in franchisees.
2 more points from Thyrocare Technologies Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Thyrocare Technologies Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Significant investments in franchisee expansion with a dedicated team of about 100 people.
- Heavy investment in cold chain logistics, including data loggers in every sample transportation box to ensure end-to-end cold chain adherence—a first nationally in diagnostics.
- Expansion and improvement of labs to reduce turnaround time from over 40 hours to 18 hours or less pan-India.
- Integration and expansion of Polo Labs and Vimta Clinical Diagnostics to increase presence in North and South India.
- Acquisition of SyncHealth to scale ECG-At-Home services and enter the pre-policy medical checkup market.
2 more points from Thyrocare Technologies Ltd's call on capex
Create a free account to keep reading this call
Fundraising & Capital Structure
See what Thyrocare Technologies Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Thyrocare Technologies Ltd said on order book & pipeline — free account, 30 seconds.
Thyrocare Technologies Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹271 Cr, net profit ₹15 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Thyrocare Tech.'s management said in earlier quarters
Others in Healthcare Services this season
- Maitreya Medica. (Q2 FY26)
23.92 crore (Page 26). Key investor presentation takeaways from Maitreya Medicare's Q2 FY26 investor presentation — and how it ranks against sector peers.
- Metropolis Healt (Q2 FY26)
Organic growth remains strong at around 12%, with no immediate price hikes planned. Key concall takeaways from Metropolis Healt's Q2 FY26 earnings call — and…
- 3B Blackbio DX Ltd (Q2 FY26)
Q2 FY 2025-26 sales: ₹3042.83 Lakh (including COVID sales ₹10.23 Lakh), up from ₹2457.55 Lakh in Q2 FY 2024-25. Key concall takeaways from 3B Blackbio DX Ltd's…
- Unihealth Hospitals Ltd (Q2 FY26)
Nashik financial closure achieved via equity and bank debt (INR 22 crores from Bank of India). Key concall takeaways from Unihealth Hospitals Ltd's Q2 FY26…
Potential multibaggers · Q2 FY27
This quarter's potential multibaggers
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Thyrocare Technologies Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Thyrocare Technologies Ltd Q2 FY26 results?
Thyrocare is currently achieving mid-teen volume growth quaterly and expects this to continue. Thyrocare expects stable margins with some seasonal dip in Q3 followed by recovery in Q4 FY '26.
What is Thyrocare Technologies Ltd share price analysis?
Thyrocare Technologies Ltd currently shows a neutral. The stock trades at a P/E of 42.7 with a market cap of ₹7,723 Cr. Investors should review the full earnings analysis for detailed insights.
Is Thyrocare Technologies Ltd planning capital expenditure?
Significant investments in franchisee expansion with a dedicated team of about 100 people.
Keep Thyrocare Technologies Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.